Dow Jones, Nasdaq, S&P 500 weekly preview: Big earnings week on tap after pullback
Jupiter Neurosciences , Inc., a pharmaceutical preparations company with a market capitalization of $24.7 million, has received a notice from NASDAQ indicating non-compliance with the exchange’s minimum bid price requirement, which could lead to delisting if not rectified. According to InvestingPro data, the stock has experienced significant pressure, falling 93% year-to-date.
On Monday, the Delaware-incorporated company, trading under the ticker (NASDAQ:JUNS), was informed by NASDAQ that its common stock had failed to maintain the minimum bid price of $1.00 for 30 consecutive business days, as observed from February 6 to March 20, 2025. Currently trading at $0.73, down from its 52-week high of $19.51, this breach of NASDAQ Listing Rule 5550(a)(2) has triggered a 180-day period, ending on September 17, 2025, for Jupiter Neurosciences to regain compliance.
To achieve this, the company’s stock must sustain a bid price of at least $1.00 for a minimum of 10 consecutive business days. If Jupiter Neurosciences fails to meet this criterion by the deadline, it may be granted additional time or face the risk of being delisted from the NASDAQ Capital Market.
Currently, the company’s stock continues to be actively traded on NASDAQ, with an average daily trading volume of 690,000 shares. Jupiter Neurosciences has stated its intention to monitor its stock’s closing price closely and is considering possible strategies to meet the NASDAQ’s minimum bid price requirement. InvestingPro analysis suggests the stock is currently overvalued, with a Fair Value assessment and 8 additional key insights available to subscribers. However, there are no guarantees provided that the company will successfully regain compliance with the minimum bid price rule or other NASDAQ listing standards.
This information is based on a press release statement from Jupiter Neurosciences, Inc. detailing the notice of potential delisting received from NASDAQ.
In other recent news, Jupiter Neurosciences has announced a strategic partnership with Aquanova AG to develop nutritional products aimed at health and longevity. This collaboration will launch its first consumer products in 2025, utilizing Jupiter’s JOTROL™, a resveratrol-based formulation. The company is also advancing JOTROL™ toward a Phase IIa clinical trial for Parkinson’s Disease, with Catalent (NYSE:CTLT) Pharma Solutions manufacturing the clinical batches required for the study. Jupiter Neurosciences has further partnered with Zina Biopharmaceuticals to support the trial’s execution and regulatory strategy.
Jupiter Neurosciences is targeting a Direct-to-Consumer product line launch in 2025, aiming to generate revenue while ongoing clinical trials continue. The company has secured $1.76 million in NIH funding and raised $11 million in December 2024 through an IPO to support its initiatives. Jupiter’s focus on the NLRP3 inflammasome in upcoming trials reflects its strategic shift towards exploring new treatments for neurodegenerative diseases. The company is also seeking partnerships in the Asia-Pacific region to expedite clinical development and regulatory approval. These recent developments illustrate Jupiter Neurosciences’ commitment to addressing unmet medical needs in CNS disorders and aging-related health solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.